摘要
目的评价射频毁损(RFA)治疗晚期原发性肝癌患者的疗效。方法采用RFA治疗41例(RFA组),以肝动脉栓塞化疗(TACE)治疗38例(TACE组)作为对照。结果RFA组总缓解率为48.78%(17/41),中位生存率为10.1个月,累计生存率:半年为58.38%,1年为33.33%,2年为9.52%;TACE组总缓解率为14.17%,中位生存期为5.1个月,累计生存率:半年为21.43%,1年为3.57%,2年为0。两组比较差异有统计学意义(P<0.05)。肝功能损害加重发生率相比:RFA组总胆红素(SB)为36.59%(15/41),谷丙转氨酶(ALT)为48.78%(20/41)和谷草转氨酶(AST)为68.29%(28/41);TACE组分别为78.95%(30/38),92.11%(35/38),84.21%(32/38),两组比较差异明显(P<0.05)。结论RFA治疗晚期原发性肝癌疗效好,毒副反应小,肝功能损害轻,是值得推广应用的介入治疗方法。
Objective To evaluate the effect of radiofrequency ablation(RFA) on patients with advanced hepatocellular carcinoma (HCC)(Child B or C). Methods Compared between RFA (n=41,RFA group) and transarterial chemoemboliation (TACE)(n=38, TACE group) in patients with HCCs. Results The remission rates of RFA group and TACE group were 48.78% and 14.17%, respectively. The median survival time were 10.1 and 5.1 months. There were significant difference between two groups in remission rates and median survival time (P<0.05 and P<0.01). The cumulative survival rates at 6 and 12 months of RFA group (58.38% and 33.33%) were different from those of TACE group (21.43% and 3.57%)(P<0.05). Hepatic functional damage in RFA group was lower than that of TACE group. Conclusion RFA has better results than that of TACE in patients with advanced HCC,which has less adverse effects and it′s worth for recommendation in wider use.
